GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Rating of "Moderate Buy" from Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) has earned an average rating of "Moderate Buy" from the eleven brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $129.2222.

• Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

Several analysts recently weighed in on the company. BTIG Research upped their price objective on GeneDx from $140.00 to $165.00 and gave the stock a "buy" rating in a research report on Wednesday, October 29th. Canaccord Genuity Group set a $160.00 target price on shares of GeneDx and gave the stock a "buy" rating in a report on Wednesday, October 29th. Wells Fargo & Company lifted their price target on shares of GeneDx from $95.00 to $140.00 and gave the company an "equal weight" rating in a report on Tuesday, November 4th. Guggenheim reiterated a "buy" rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of GeneDx in a research report on Wednesday, October 8th.

Get Our Latest Analysis on WGS

Insider Transactions at GeneDx

• GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play

In related news, CEO Katherine Stueland sold 2,158 shares of the business's stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $136.54, for a total transaction of $294,653.32. Following the sale, the chief executive officer owned 3,436 shares in the company, valued at $469,151.44. The trade was a 38.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Casdin Capital, Llc sold 500,000 shares of GeneDx stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $120.90, for a total value of $60,450,000.00. Following the sale, the director directly owned 3,007,164 shares in the company, valued at $363,566,127.60. The trade was a 14.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 556,375 shares of company stock worth $67,569,247. Insiders own 29.60% of the company's stock.

Hedge Funds Weigh In On GeneDx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. increased its stake in shares of GeneDx by 25.8% in the 1st quarter. Raymond James Financial Inc. now owns 333,376 shares of the company's stock valued at $29,525,000 after acquiring an additional 68,331 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in GeneDx by 150.9% during the second quarter. Harbor Capital Advisors Inc. now owns 39,979 shares of the company's stock worth $3,690,000 after acquiring an additional 24,042 shares in the last quarter. MRA Advisory Group acquired a new stake in GeneDx in the second quarter worth $298,000. Jacobs Levy Equity Management Inc. bought a new stake in GeneDx in the first quarter valued at $488,000. Finally, Fred Alger Management LLC raised its holdings in shares of GeneDx by 2.0% during the first quarter. Fred Alger Management LLC now owns 557,018 shares of the company's stock valued at $49,332,000 after purchasing an additional 10,964 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Stock Performance

NASDAQ WGS opened at $133.63 on Thursday. The firm's 50 day simple moving average is $126.24 and its 200 day simple moving average is $102.70. The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of 1,484.78 and a beta of 2.01. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. GeneDx has a 1 year low of $55.17 and a 1 year high of $147.71.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.21. The firm had revenue of $116.74 million during the quarter, compared to analysts' expectations of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. GeneDx has set its FY 2025 guidance at EPS. As a group, research analysts expect that GeneDx will post 0.97 earnings per share for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Stories

• Five stocks we like better than GeneDx
• Options Trading - Understanding Strike Price
• onsemi Places a $6 Billion Bet on Its Own Stock
• How to Invest in Small Cap Stocks
• HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
• Stock Dividend Cuts Happen Are You Ready?
• End the Year Strong With These 3 Comeback Champions

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GeneDx Right Now?

Before you consider GeneDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.

While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here